All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Glenmark's Ryaltris (olopatadine/mometasone furoate) wins China NMPA approval for moderate to severe allergic rhinitis treatment
Small molecule, allergic rhinitis, nasal spray, combination therapy, respiratory - Read more

THE GOOD
Business Development & Partnerships

SOPHiA GENETICS, Element Biosciences, Complete Genomics partner on AI-powered sequencing for precision medicine research
Research collaboration, oncology, AI/ML, rare disease, diagnostics - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

CeleCor Therapeutics' zalunfiban shows Ph3 success for segment elevation myocardial infarction, eyes 2026 FDA filing
Small molecule, cardiovascular, antiplatelet therapy, myocardial infarction, glycoprotein IIb/IIIa receptor - Read more

Pfizer launches Ph3 trials of PF-08634404 (PD-1xVEGF bispecific) targeting non-small cell lung cancer as part of strategy to replace Keytruda
Bispecific antibody, cancer, PD-1xVEGF bispecific, non-small cell lung cancer, immunotherapy - Read more

Teva's AUSTEDO (deutetrabenazine) shows real-world improvements in tardive dyskinesia patients in Ph4 registry study
Small molecule, neurological, deutetrabenazine, tardive dyskinesia, VMAT2 inhibitor - Read more

UbiVac's DPV-001 dark genome cancer vaccine shows improved survival in head and neck squamous cell carcinoma
Vaccine, cancer, cancer vaccine, head and neck squamous cell carcinoma, checkpoint inhibitor combination, dark genome antigens - Read more

Calliditas Therapeutics reports positive Ph2a safety data for setanaxib in Alport syndrome patients at ASN conference
Small molecule, rare kidney disease, NOX inhibitor, Alport syndrome, proteinuria reduction - Read more

enGene's detalimogene voraplasmid shows 63% response rate in Ph3 bladder cancer trial, 2026 filing planned
Gene therapy, cancer, non-viral gene therapy, bladder cancer, BCG-unresponsive, non-muscle invasive bladder cancer - Read more

InflaRx reports positive Ph2a results for INF904 targeting complement C5aR in hidradenitis suppurativa and chronic spontaneous urticaria
Small molecule, autoimmune, C5aR antagonist, hidradenitis suppurativa, chronic spontaneous urticaria, complement system - Read more

THE GOOD
Earnings & Finances

KalVista's Ekterly generates $13.7M Q3 revenue, tripling Wall Street expectations for hereditary angioedema drug
Small molecule, rare disease, revenue impact, financial - Read more [Paywall]

THE GOOD
Fundraises

Vor Bio raises $100M public offering, transforming autoimmune disease treatment
Autoimmune, clinical-stage, biotechnology - Read more

Surv Biopharma raises $12M Series B first close, advancing oncolytic virus therapies
Oncolytic virus, oncology, clinical-stage - Read more

INOVIO announces proposed public offering, DNA medicines for HPV/cancer/infectious diseases
DNA medicines, HPV-related diseases, cancer, infectious diseases - Read more

THE GOOD
Lawsuits

Novo Nordisk wins decade-long hemophilia fraud case after jury clears NovoSeven promotion practices
Recombinant protein, rare disease, legal resolution, operational - Read more

THE GOOD
Mergers & Acquisitions

Mallinckrodt and Endo complete $6.7B merger, rebrand as Keenova and spin off Par Health generics business
Generics, rare disease, strategic, major transaction - Read more

THE GOOD
Politics & Policy

UK unveils five-year roadmap to replace animal testing with AI and 3D tissue models
Alternative methods, drug development, strategic, operational - Read more

THE GOOD
Regulatory

FDA appoints Richard Pazdur as CDER director, replacing ousted George Tidmarsh amid conduct probe
Oncology, strategic, operational - Read more

THE BAD
Clinical Trials

Novo Nordisk's coramitug shows mixed Ph2 results for transthyretin amyloidosis with cardiomyopathy treatment
Antibody, cardiovascular, monoclonal antibody, transthyretin amyloidosis, heart failure, TTR protein - Read more

THE BAD
Mergers & Acquisitions

Neuphoria receives $5.20 per share buyout offer from Lynx1 after phase 3 trial failure
Small molecule, neurological, strategic, major transaction - Read more

THE BAD
Strategic Plans

CRISPR Therapeutics discontinues CD70-targeting CTX131 program to focus on higher-potential pipeline assets
CAR-T, oncology, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here